Merck Sees No Future for NGM Bio’s Eye Drugs and Declines Licensing Options
Geographic atrophy has no FDA-approved treatments, and Merck is walking away from its contender in the chase for one. The pharmaceutical giant declined to exercise its option on several NGM Biopharmaceuticals eye programs, a decision that follows a Phase 2 clinical trial failure.